Cancer Research Annual Meeting 2010  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graff, C. P.
Right arrow Articles by Wittrup, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graff, C. P.
Right arrow Articles by Wittrup, K. D.
[Cancer Research 63, 1288-1296, March 15, 2003]
© 2003 American Association for Cancer Research


Experimental Therapeutics

Theoretical Analysis of Antibody Targeting of Tumor Spheroids

Importance of Dosage for Penetration, and Affinity for Retention1

Christilyn P. Graff and K. Dane Wittrup2

Department of Chemical Engineering and Division of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

The interplay among antibody/antigen binding kinetics, antibody diffusion, and antigen metabolic turnover together determines the depth of penetration of antitumor antibodies into prevascular tumor spheroid cell clumps. A sharp boundary between an outer shell of bound high-affinity antibody and an inner antibody-free core has been previously observed and mathematically modeled and was termed the "binding site barrier." We show here that this process is well described by a simplified shrinking core model wherein binding equilibration is much more rapid than diffusion. This analysis provides the following experimentally testable predictions: (a) the binding site barrier is a moving boundary whose velocity is proportional to the time integral of antibody concentration at the spheroid surface (i.e. plasma antibody AUC); (b) the velocity of this moving boundary is independent of binding affinity, if the affinity is sufficiently high to strongly favor antibody/antigen complex formation at prevailing antibody concentrations; and (c) maximum tumor retention is achieved when the antibody/antigen dissociation rate approaches the rate of antigen metabolic turnover. The consistency of these predictions with published experimental results is demonstrated. The shrinking core model provides a simple analytic relationship predicting the effects of altered antibody pharmacokinetics, antibody molecular weight, antigen turnover rate, antigen expression level, and micrometastasis size on antibody penetration and retention. For example, a formula is provided for predicting the bolus dose necessary to accomplish tumor saturation as a function of antibody and tumor properties. Furthermore, this analysis indicates certain attributes necessary for an optimal tumor targeting agent.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. M. Schmidt and K. D. Wittrup
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Mol. Cancer Ther., October 1, 2009; 8(10): 2861 - 2871.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. M. Kim, C. F. McDonagh, L. Westendorf, L. L. Brown, D. Sussman, T. Feist, R. Lyon, S. C. Alley, N. M. Okeley, X. Zhang, et al.
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Mol. Cancer Ther., August 1, 2008; 7(8): 2486 - 2497.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. E. Ackerman, D. Pawlowski, and K. D. Wittrup
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Mol. Cancer Ther., July 1, 2008; 7(7): 2233 - 2240.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. M. Thurber and K. D. Wittrup
Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids
Cancer Res., May 1, 2008; 68(9): 3334 - 3341.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
M. Chodorge, L. Fourage, G. Ravot, L. Jermutus, and R. Minter
In vitro DNA recombination by L-Shuffling during ribosome display affinity maturation of an anti-Fas antibody increases the population of improved variants
Protein Eng. Des. Sel., May 1, 2008; 21(5): 343 - 351.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. El Emir, U. Qureshi, J. L.J. Dearling, G. M. Boxer, I. Clatworthy, A. A. Folarin, M. P. Robson, S. Nagl, M. A. Konerding, and R. B. Pedley
Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas
Cancer Res., December 15, 2007; 67(24): 11896 - 11905.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
G. M. Thurber, S. C. Zajic, and K. D. Wittrup
Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases
J. Nucl. Med., June 1, 2007; 48(6): 995 - 999.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. Dennis, H. Jin, D. Dugger, R. Yang, L. McFarland, A. Ogasawara, S. Williams, M. J. Cole, S. Ross, and R. Schwall
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Cancer Res., January 1, 2007; 67(1): 254 - 261.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun
PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING
J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. J. Lammerts van Bueren, W. K. Bleeker, H. O. Bogh, M. Houtkamp, J. Schuurman, J. G.J. van de Winkel, and P. W.H.I. Parren
Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action.
Cancer Res., August 1, 2006; 66(15): 7630 - 7638.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
A. Nguyen, A. E. Reyes II, M. Zhang, P. McDonald, W. L. T. Wong, L. A. Damico, and M. S. Dennis
The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin
Protein Eng. Des. Sel., July 1, 2006; 19(7): 291 - 297.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
L. A. Kunz-Schughart, J. P. Freyer, F. Hofstaedter, and R. Ebner
The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model
J Biomol Screen, June 1, 2004; 9(4): 273 - 285.
[Abstract] [PDF]


Home page
Protein Eng Des SelHome page
C. P. Graff, K. Chester, R. Begent, and K.D. Wittrup
Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37{degrees}C
Protein Eng. Des. Sel., April 1, 2004; 17(4): 293 - 304.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.